Lorlatinib is a Small Molecule owned by Pfizer, and is involved in 41 clinical trials, of which 17 were completed, 23 are ongoing, and 1 is planned.

Lorlatinib is a ATP competitive inhibitor of the receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Lorlatinib binds to and inhibits ALK kinase. The kinase inhibition leads to disruption of ALK mediated signaling and eventually inhibits tumor cell growth in ALK overexpressing tumor cells. ALK dysregulation and gene rearrangements are associated with a series of tumors.

The revenue for Lorlatinib is expected to reach a total of $8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lorlatinib NPV Report.

Lorlatinib is originated and owned by Pfizer.

Lorlatinib Overview

Lorlatinib (Lorviqua / Lorbrena/ Lorlak) is a kinase inhibitor act as anti-neoplastic agent. It is formulated as tablets, coated tablets, film coated tablets for oral route of administration. It is indicated for the treatment of unresectable advanced or recurrent ALK fusion gene positive non-small cell lung cancer unresectable advanced or recurrent fusion gene positive, resistance or intolerance to ALK tyrosine kinase inhibitors, and also for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or alectinib as the first ALK inhibitor therapy for metastatic disease, or ceritinib as the first ALK inhibitor therapy for metastatic disease. Lorbrena is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

Lorlatinib (PF-06463922) is under development for the treatment of metastatic non-small cell lung cancer, anaplastic large cell lymphoma, neuroblastoma . The drug candidate is a new molecular entity (NME). The drug candidate is administered orally as a tablet. It is an ATP competitive small molecule inhibitor of anaplastic lymphoma kinase (ALK). It was under development for the treatment of lymphoma and glioblastoma multiforme.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Lorlatinib

Report Segments
  • Innovator (NME)
Drug Name
  • Lorlatinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.